


ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18
 Stylesheet Version v18.0



Title of Invention	Thio-siRNA Aptamers
-----------------------	---------------------

Application Number: 10/758488

Confirmation Number: 5963

First Named Applicant: David Gorensetin

Attorney Docket Number: UTMB:1019

Search string: (5218088 or 5397698 or 5576302 or 5587361
 or 5599797 or 5602000 or 5607923 or 5620963
 or 5635488 or 5639873 or 5660985 or 5661134
 or 5705337 or 5734041 or 5763595 or 5797721
 or 5804445 or 5853984 or 5874219 or 6242246
 or 6423493 or 6503715 or 6506559 or 6544776
 or 6573099 or 20020028919 or 20020086356 or
 20020132788 or 20030051263 or 20030055020
 or 20030056235 or 20030059944 or
 20030068821 or 20030092180 or 20031008923
 or 20030162216).pn.



Certification: This Information Disclosure Statement was submitted under the following conditions, which satisfies the requirement under 37 CFR 1.97(e). The filer certified:

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
TV	1	5218088	1993-06-08	Gorenstein			
I	2	5397698	1995-03-14	Goodman			
↓	3	5576302	1996-11-19	Cook			

Dracy Wilkerson

3/8/06

TV	4	✓	5587361	1996-12-24	Cook
	5	✓	5599797	1997-02-04	Cook
	6	✓	5602000	1997-02-11	Hyman
	7	✓	5607923	1997-03-04	Cook
	8	✓	5620963	1997-04-15	Cook
	9	✓	5635488	1997-06-03	Cook
	10	✓	5639873	1997-06-17	Barthcut
	11	✓	5660985	1997-08-26	Pieken
	12	✓	5661134	1997-08-26	Cook
	13	✓	5705337	1998-01-06	Gold
	14	✓	5734041	1998-03-31	Just
	15	✓	5763595	1998-06-09	Gold
	16	✓	5797721	1998-08-18	Rabin
	17	✓	5804445	1998-09-08	Brasier
	18	✓	5853984	1998-12-29	Davis
	19	✓	5874219	1999-02-23	Rava
	20	✓	6242246	2001-06-05	Gold
	21	✓	6423493	2002-07-23	Gorenstein
	22	✓	6503715	2003-01-07	Gold
	23	✓	6506559	2003-01-14	Fire
	24	✓	6544776	2003-04-08	Gold
✓	25	✓	6573099	2003-06-03	Graham

US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
TV	1	✓	20020028919	2002-03-07	Matulic-Admic		
	2	✓	20020086356	2002-07-04	Tuschl		
	3	✓	20020132788	2002-09-19	Lewis		
	4	✓	20030051263	2003-03-13	Fire		
	5	✓	20030055020	2003-03-20	Fire		
	6	✓	20030056235	2003-03-20	Fire		
	7	✓	20030059944	2003-03-27	Lois-Caballe		
	8	✓	20030068821	2003-04-10	Lois-Caballe		
✓	9	✓	20030092180	2003-05-15	Lewis		

Dracy Wilkerson

8/8/06

	10	20031008923	2003-06-12	Tuschi
<input checked="" type="checkbox"/>	11	20030162216	2003-08-28	Gold

Signature

Examiner Name	Date
<i>Tracy Wilensz</i>	3/8/06



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	UTMB:1019
-------	---	----	---	------------------------	-----------

Complete if Known

Application Number	
Filing Date	5/20/2004
First Named Inventor	Gorenstein et al.
Art Unit	
Examiner Name	
Attorney Docket Number	UTMB:1019

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
TV		WO 00 47774 A1	8/17/2000	Janjic, et al.		
		WO 92 14842 A	9/3/1992	Toole, et al.		
		WO 92 14843	9/3/1992	Toole, et al.		
		WO 93 08296 A	4/29/1993	Hoke, et al.		
		WO 96 19572 A	6/27/1996	Hybridon		
		WO 96 41019 A1	8/17/2000	Janjic, et al.		
		WO 99 31275	6/24/1999	Gold, et al.		

Examiner Signature		Date Considered	3/8/06
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				Filing Date 5/20/2004	
				First Named Inventor Gorenstein et al.	
				Art Unit	
				Examiner Name	
(Use as many sheets as necessary)				Attorney Docket Number UTMB:1019	
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TU		ANTSYPOVICH, ET AL. (1998) Cross-linked DNA duplexes: Exonuclease stability and interaction with the nucleic transcription factor of the κ light-chain enhancer (NF- κ B).	
		BIELINSKA, ET AL. (1990) Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides, <i>Science</i> , Vol. 250, pg. 997-1000.	
		KHALED, ET AL. (1998) Use of Phosphorothioate-Modified Oligodeoxynucleotides to inhibit NF- κ B Expression and Lymphocyte Function, <i>Clinical Immunology and Immunopathology</i> , Vol. 86, No. 2, pp. 170-179.	
		KING, ET AL., (1998) Novel Combinatorial Selection of Phosphorothioate Oligonucleotide Aptamers. <i>Biochemistry</i> , 37, 16489-16493.	
		KUNSCH, ET AL. (1992) Selection of Optimal κ B/Rel DNA-Binding Motifs: Interaction of Both Subunits of NF- κ B with DNA is Required for Transcriptional Activation, <i>Molecular and Cellular Biology</i> , October 1992, Vol. 12, No. 10, p. 4412-4421.	
		LEBRUSKA, ET AL. (1999) Selection and Characterization of an RNA Decoy for Transcription Factor NF- κ B ⁺ , <i>Biochemistry</i> , 38, 3168-3174.	
		MORISHITA, ET AL. (1997) In vivo transfection of cis element "decoy" against nuclear factor- κ B binding site prevents myocardial infarction, <i>Nature Medicine</i> , Vol. 3, No. 8, p. 894-899.	
		NAKAMAYE, ET AL. (1988) Direct sequencing of polymerase chain reaction amplified DNA fragments through the incorporation of deoxynucleoside α -thiotriphosphates, <i>Nucleic Acids Research</i> , Vol. 16, No. 21.	
		SHARMA, ET AL. (1996) Transcription Factor Decoy Approach to Decipher the Role of NF- κ B in Oncogenesis, <i>Anticancer Research</i> , 16:61-70.	
		STEC, ET AL. (1997) Deoxyribonucleoside 3'-O-(2-Thio- and 2-Oxo-"spiro"-4,4-pentamethylene-1,3,2-oxathiaphospholane)s: Monomers for Stereocontrolled Synthesis of Oligo(deoxyribonucleoside phosphorothioate)s and Chimeric PS/PO Oligonucleotides ⁵ , <i>J. Am. Chem. Soc.</i> , 120, 7156-7167.	
		UHLMANN, ET AL. (1997) Studies on the Mechanism of Stabilization of Partially Phosphorothioated Oligonucleotides Against Nucleolytic Degradation, <i>Antisense & nucleic Acid Drug Development</i> , 7:345-350.	
		ZON, GERALD (1988) Oligonucleotide Analogues as Potential Chemotherapeutic Agents. <i>Pharmaceutical Research</i> , Vol. 5, No. 9, pp. 539-549.	

Examiner Signature		Date Considered	3/8/06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.